Federal Contractor Profile
Basilea Pharmaceutica Ag
Federal contracting record: $254M obligated across 4 awards from 1 agencies, FY 2016–2026.
$254M
Total Obligated
4
Award Records
1
Agencies Served
2
NAICS Codes
Company Profile
Parent UEI (Unique Entity Identifier)
Z9A6DMV55YP3
CAGE Code
SSU10
Address
GRENZACHERSTRASSE 487, BASEL, 4058
First Federal Award
Apr 19, 2016
Most Recent Award
Aug 4, 2026
Federal Sales Analytics
Toggle between trend, agency drilldown, and treemap. Use the period selector to focus the time window.
Hover any bar for YoY change + award count. Current fiscal year shown at reduced opacity (partial year).
Top Federal Agencies
- Department of Health and Human Services$254M
100.0% of total obligations
Recent Federal Awards
| Date | Agency | NAICS | Description | Amount |
|---|---|---|---|---|
| Aug 4, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. | $5.4M |
| Jul 28, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA | $30M |
| May 27, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. | $13M |
| Feb 24, 2026 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | VENATORX PHARMACEUTICALS: NEW ANTIBIOTICS TO TREAT DRUG-RESISTANT GRAM-NEGATIVE BACTERIA INCLUDING PUBLIC HEALTH PATHOGENS. | $6.1M |
| Sep 15, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA | $25M |
| Jul 7, 2025 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA | $39M |
| Sep 18, 2024 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541714 | THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA | $29M |
| Sep 28, 2022 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $3.2M |
| Aug 6, 2021 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $4.3M |
| Sep 16, 2020 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $1.5M |
| Sep 30, 2019 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $8.0M |
| Sep 11, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $10M |
| Feb 14, 2018 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $10M |
| Jun 6, 2017 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $55M |
| Apr 19, 2016 | Department of Health and Human ServicesBARDA - ASPR / DAAPPO / BARDA DCMA | 541711 | IGF::OT::IGF ADVANCED DEVELOPMENT OF CEFTOBIPROLE | $20M |
Want to win work like Basilea Pharmaceutica Ag?
Their contracts will eventually end — and when they do, the government has to award that work again. Mindy tells you up to a year early, so you can be ready to compete for it.